Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum provided. Revenue depends entirely on actual prescriptions and discounts agreed.
Open-house agreements automatically terminate if a competitive discount agreement for the same substance takes effect (...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2027
- Supply of pharmaceutical products containing Golimumab (ATC L04AB06)
- Conclusion of non-exclusive discount agreements under §130a Abs. 8 SGB V
Show full summary
Open-house model for non-exclusive discount agreements (Rabattverträge) on Golimumab (ATC L04AB06) with AOK Bayern. All interested pharmaceutical companies meeting eligibility can conclude identical, non-negotiable contracts. No competitive selection; contracts can be entered at any time until 05.02.2027, subject to rolling submission deadlines. Estimated value not provided. Contract duration 01.04.2025 to 31.03.2027. The procedure is not subject to public procurement law; it is a voluntary open-house model.
Risks
No estimated value or framework maximum provided. Revenue depends entirely on actual prescriptions and discounts agreed.
Open-house agreements automatically terminate if a competitive discount agreement for the same substance takes effect (...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
Administrative
- Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Contract must be submitted in duplicate (paper) or with qualified electronic signature
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Golimumab, ATC L04AB06
Non-exclusive discount agreements for the active substance Golimumab (ATC L04AB06) for pharmaceutical companies. Contracts start monthly if documents are complete by the 5th of the month. Deadline for contract conclusion: 05.02.2027. Contract duration: 01.04.2025 to 31.03.2027.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich!
Procurement Details
- Publication date
- 17 Feb 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 106852-2025
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No estimated value or framework maximum provided. Revenue depends entirely on actual prescriptions and discounts agreed.
Open-house agreements automatically terminate if a competitive discount agreement for the same substance takes effect (...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications